Metrnl Reduces Thrombosis and Acute Myocardial Injury Through Inhibition of Platelet Activation via CD36 Receptor Degradation.

Metrnl inhibits platelet activation and thrombosis by promoting CD36 degradation, reducing microvascular thrombosis and myocardial injury in mice.

• Why it matters: Understanding how to prevent thrombosis without increasing bleeding risk is critical for treating cardiovascular diseases like myocardial infarction, where current therapies have limitations.
• What they did: Researchers used knockout mice, recombinant proteins, and molecular assays to investigate Metrnl's effects on platelets and thrombosis, identifying CD36 as its receptor and elucidating its mechanism.
• The result: Metrnl effectively reduces platelet activation and thrombus formation by inducing CD36 degradation, offering a promising new therapeutic approach for thrombotic conditions without bleeding complications.